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MATIAS eT Al. Rabbani et al., 2014) . The overall diagnostic yield of WES has been shown to range from 21% for proband-only to 37% for trio analysis (Iglesias et al., 2014; Lee et al., 2014; Retterer et al., 2016; Yang et al., 2014) , and can exceed 50% when considering specific patient phenotypes such as hearing loss or neurometabolic disorders (Farwell et al., 2015; Iglesias et al., 2014; Retterer et al., 2016; Tarailo-Grovac et al., 2016; Thevenon et al., 2016) . In addition to identifying a diagnosis underlying the patient's symptoms, secondary findings may also be identified (Green et al., 2013) . The American College of Medical Genetics (ACMG) recommends that laboratories offering WES specifically investigate 59 genes that show evidence of causing severe disease that is actionable and possibly preventable if identified before symptoms begin (Kalia et al., 2017) . Both primary and secondary findings have been presumed to prompt specific and targeted medical management changes for patients and their families, although there are few studies to date that discuss these changes in detail (Dixon-Salazar et al., 2012; Iglesias et al., 2014; Valencia et al., 2015) .
WES has been shown to be cost-effective and superior in diagnostic yield when compared to the traditional diagnostic trajectory in several different patient populations (Monroe et al., 2016; Stark et al., 2017; Vissers et al., 2017) . In addition to being cost-effective, demonstrating the clinical utility of WES requires that it also be studied for its impact on patient management in order to be widely implemented and covered by third party payors. While other genetic testing methodologies, such as chromosomal microarray (CMA), have been well-studied for impact on medical management and shown to impact management for up to 70% of patients (Coulter et al., 2011; Henderson et al., 2014; Saam, Gudgeon, Aston, & Brothman, 2008) , limited studies have previously reported that positive WES results prompt changes to medical management recommendations for patients (Iglesias et al., 2014; Valencia et al., 2015) . Valencia et al. (2015) analyzed 40 patients with WES results, 12 of whom had positive results. Medical management, which included receiving genetic counseling (GC) and ending the diagnostic odyssey in addition to changing imaging recommendations and/or medication (s) and initiation of subspecialty consults, was reported to be altered for all participants with positive results. Iglesias et al. (2014) 
also
found that all 37 patients in their study with positive WES results received some sort of change to management, including discontinuing further diagnostic investigations, initiation of screening for additional symptoms, changes to their treatment, identifying other family members with the same condition or who were carriers of the condition, and assisting in reproductive planning. There have also been a number of studies that have reported high diagnostic yield rates in their specific patient cohorts as well as targeted interventions and changes/redirection to patient care for a subset of those patients including preventive measures, referral to specialists, medication/dietary modifications, life-saving procedures, and treatments targeting the abnormality at a cellular or molecular level (Meng et al., 2017; Stark et al., 2018; Tarailo-Graovac et al., 2016) . Besides medical management changes, receiving a molecular diagnosis has GC implications and allows for options that were not previously available (Dixon-Salazar et al., 2012; Stark et al., 2016) . One of the major familial impacts of genomic diagnosis is providing parents with reproductive knowledge and options, including the ability to make decisions about future pregnancies and pursue targeted testing either during the preimplantation stage or prenatally (Stark et al., 2018) . In fact, Stark et al. (2018) discuss how families whose child received a diagnosis from WES utilized more genetic services and had more subsequent pregnancies compared to families whose child did not receive diagnostic WES results. Receiving a specific diagnosis also allows for identification of diagnosis-specific support groups, which allow families to meet others in a similar situation who can provide empathy, support, and firsthand experiences (Plumridge, Metcalfe, Coad, & Gill, 2011) . The interpretation of management is variable and often somewhat limited, and it may be reasonable to expand the meaning of management to go beyond changes in treatment to include psychosocial and familial outcomes (Nguyen & Charlebois, 2015 of a positive finding were excluded given that the time constraints of the study limited the total number of participants that could be included, so the focus of this study was on results that contained a lesser degree of uncertainty.
| MATERIAL S AND ME THODS

| Participants
| Participant selection process
The CCHMC Molecular Genetics Laboratory's records were used to identify possible participants for the study. Eligible participants (n = 102) were sorted into two groups based on their WES results (Figure 1 ). Individuals with negative results with no VUS's were categorized as negative (n = 54), and individuals with pathogenic or likely pathogenic variants identified as a primary finding and/or secondary finding, with or without VUS's, were categorized as positive (n = 48).
Additional participants were excluded due to inability to match phenotype, having no information in the EMR, blood relationship to another proband, or WES result being reclassified following the initial results reporting. After all exclusions, 37 participants with positive results and 41 with negative results remained for analysis.
| Medical record review
An online secure, web-based database (Research Electronic Data Capture) was created to store the data collected for the study (Harris et al., 2009) . Demographic data were first collected, followed by data regarding medical management and GC options both pre-and post-WES results for all study variables except specialist referrals, which were recorded only post-WES results. "Medical management" was defined as genetic testing, imaging testing, metabolic testing, specialist referrals, lifestyle recommendations, and recurrence risk. For imaging testing, skeletal surveys, bone age X-rays, brain MRIs, echocardiograms, abdominal ultrasounds, and renal ultrasounds were collected. For metabolic testing, urine organic acids, serum amino acids, and acylcarnitine profiles were collected. "GC options" were defined as reproductive options such as targeted prenatal diagnostic testing and preimplantation genetic diagnosis (PGD), targeted testing availability for family members, and access to diagnosis-specific support groups. All variables were recorded in a binary (yes or no) fashion based upon whether each recommendation was available pre-and post-WES results. All medical management variables except recurrence risk were primarily collected from information in the medical records, while recurrence risk and all GC options variables were primarily deduced based on clinical judgment.
| Alternative data collection strategies
There were five participants (6.4%) whose EMR's did not contain comprehensive data on the desired variables; thus, alternative data collection strategies were utilized (Supporting Information Figure S1 ). These included consulting published clinical practice guidelines for a patient's given diagnosis or diagnoses, if available, and consulting an expert panel of three geneticists at CCHMC who came to a consensus as to whether medical management changes should be made for each patient based on their WES results.
During the final stage of data collection, the expert panel was ParƟcipants with no records idenƟfied in electronic medical record (EMR) system excluded restrict medical management recommendations and GC options to data pertaining to the positive result, and they also reviewed all diagnoses in the positive group to determine if avoidance or initiation of a targeted medication or surgery would be recommended, as these data were not collected from the EMR. 
| Statistical analysis
Number of samples analyzed 0.07 
TA B L E 1 Patient demographics and clinical characteristics
or mean (SD) for continuous variables depending on the distribution.
The primary outcome variables examined included genetic testing, imaging, metabolic testing, specialist referrals, lifestyle recommendations, recurrence risk, reproductive options, testing available for family members, and support groups. In the positive and negative groups, the difference in each of the outcome variables pre-to post-WES results was examined using McNemar's tests. To assess the impact of the WES results on the pre-to post-WES differences, the participants were assigned "change" or "no change" for each of the variables according to whether they had differences in the variable pre-to post-WES. "Change" indicated the variable was either only recommended after WES or was only recommended before WES, indicating there was a difference in the variable for that participant before and after WES results. "No change" indicated the variable was neither recommended before nor after WES results or was recommended both before and after WES results, indicating there was no difference in the variable before and after WES for that participant.
The proportions of individuals that received change(s) were then compared between the positive and negative group using Fisher's 
| RE SULTS
The final study cohort included 78 participants, 37 (47%) of whom had positive WES results and 41 (53%) of whom had negative WES results. No statistically significant differences in demographics were found between the positive and negative groups ( 
| Medical management
Medical management variables were examined pre-and post-WES among the positive group and the negative group using McNemar's tests. A significant difference pre-to post-WES was detected for all medical management categories for participants with positive results ( Table 3 ). The majority of differences in genetic testing, imaging, and metabolic testing were discontinuation of testing, while all differences in lifestyle recommendations and recurrence risk were initiation of these recommendations. For participants with negative results, a significant difference was detected in genetic testing, imaging, and metabolic testing ( Table 3 ). All of the differences in these categories were discontinuation of testing.
To compare the changes in management between the positive and negative groups, participants were categorized into the two groups of "change" or "no change" for each outcome variable that was analyzed in the pre-to post-WES fashion. Between the positive and negative groups, Fisher's exact test identified a marginally significant difference in specialist referrals (p = 0.05) and a significant difference in recurrence risk (p < 0.001) ( family members in the negative group. However, the raw frequencies demonstrate that the majority of these participants did not have the availability of these variables either pre-or post-WES.
TA B L E 3 Differences in pre-to post-WES proportions of the presence or absence of medical management recommendations and GC options in the positive and negative groups
| GC options for patients and families
GC options were examined pre-and post-WES among the positive and negative result groups using McNemar's tests. A significant increase from pre-to post-WES was detected in the availability of all GC options (reproductive options, testing for family members, and support groups) for participants with positive results, while a significant difference was not detected in availability of any GC options for participants with negative results (Table 3) .
Participants were split into the same two groups of "change"
and "no change" to test whether there was any difference between the positive and negative groups. Consistent with data shown in Table 3 , statistically significant differences between the positive and negative groups were found in all GC options variables (Table 4) .
Regardless of WES results, the overall proportion of participants with at least one difference in GC options was 49%. Changes to medical management analyzed in these studies included specialist referrals, ability to provide a revised recurrence risk, changes to medical screening, changes to genetic and/or diagnostic testing, and imaging/lab tests. However, the CMA studies analyzed management only following testing results. The current study may have been able to detect changes that would be missed by a medical record review or survey that only considers documentation after the testing of interest has been completed; however, it is important to note that it is not possible with the current study to discern if all the differences detected were due to WES results or if other factors played a role. Furthermore, in addition to the proportion of patients experiencing a difference in management and/or options following testing, CMA and sequencing-based genetic tests have been shown to prompt different types of post-testing activities. Hayeems et al.
| D ISCUSS I ON
(2017) described the types of healthcare activities done following pediatric whole genome sequencing (WGS) compared to CMA and found that CMA was more likely to prompt additional testing and diagnostic investigations, while WGS was more likely to prompt tailored care such as subspecialist referrals. Delineating not only how frequent post-test healthcare changes are but the types of healthcare changes are an important factor in determining clinical utility.
Both the positive and negative groups were observed to experience significant pre-to post-WES differences in genetic testing, imaging, and metabolic testing. For the negative group, all of these differences were discontinuation of recommendations following WES results. For the positive group, all differences seen in genetic testing and metabolic testing were discontinuation of testing. For imaging, the majority was also discontinuation (82%), but some (18%) differences were initiation of new imaging. Because participants with both positive and negative WES results had similar differences in pre-to post-WES genetic testing, imaging, and metabolic testing, there was no significant difference between the two groups. Both positive and negative WES results can be informative to the clinician; besides the clear implications of a positive result being informative by providing a genetic diagnosis, a negative result may also be informative because it can decrease the suspicion for a number of diagnoses that were suspected prior to the testing being performed. This may allow the clinician to be reassured that testing or screening that had been recommended due to a suspected diagnosis may be discontinued or changed based on this new information from the negative WES result.
TA B L E 4 Comparison of differences in medical management and GC options following WES results between positive and negative WES results
Positive
However, other reasons for discontinuation of testing following WES are possible. Negative imaging studies or metabolic studies may be reassuring to the clinician and prevent additional testing regardless of if the patient received WES testing. Additionally, because only certain types of imaging and metabolic tests were collected for this study, it is possible that other types of imaging and metabolic testing were ordered for patients after WES that would not have been recorded in this study. It is also important to note that not all negative WES results provide reassurance of the absence of a monogenic disorder; for some, there is an ongoing suspicion of a genetic syndrome that was not detected on WES, and uncertainty and diagnostic investigations persist for the patient. For some patients who fall into this category, however, uninformative WES results have the potential to aid in diagnosis of a non-monogenic disorder. While the finding of negative WES results leading to differences in testing aspects of medical management was unanticipated, the impact of negative results may be even broader. In a study investigating clinical outcomes in children who underwent genomic sequencing early in the diagnostic trajectory, it was found that uninformative (negative) WES results aided in supporting the diagnosis of non-Mendelian disorders in 8.75%
of the total cohort (Stark et al., 2018) . The diagnosis of a non-genetic condition allowed these patients to avoid further investigations and unnecessary treatments, which further adds benefit by reducing healthcare costs. The benefit of negative WES results, while perhaps unexpected, should not be overlooked.
In addition to the three testing categories, statistically significant pre-to post-WES differences were identified for participants with positive results in all other medical management and GC categories as well. Because only the positive group experienced differences to these additional categories, there were significant differences between the positive and negative groups in these variables. Some of the differences observed in the positive group can be predicted based on the implications of having a genetic diagnosis, such as being able to perform targeted testing for a future pregnancy or an at-risk family member. Additionally, a positive WES result has the potential to alter a presumed diagnosis for a patient. In this study, eight of the 13 patients with a presumed diagnosis in the positive group received a change to their diagnosis, resulting in the possibility that their management may also change. Patient 41 had a presumed diagnosis of Moebius syndrome but upon receiving WES results received an altered diagnosis of Congenital Myasthenic Syndrome (OMIM #608931) due to pathogenic variants in the CHRNE gene. This corrected diagnosis was imperative to the patient's management, as a new medication was initiated that was targeted to the underlying genetic cause. A similar situation was described where a patient was able to discontinue chemotherapy after a diagnosis was corrected by WES (Sawyer et al., 2016) . These examples indicate that a corrected diagnosis on WES has the potential both to initiate an appropriate and targeted treatment for a patient as well as to prevent inappropriate and potentially harmful interventions.
Participants with positive results were more likely (p = 0.05) to obtain referrals to specialists than individuals with negative results.
Positive results may help the patient's healthcare providers to better understand the underlying etiology for their condition and can spur additional screening recommendations and referrals to specialists who can appropriately manage their care. In one study, it was reported that over 50% of patients with positive CMA results received specialist referrals after receiving their test results, and it is expected that these referrals would lead to an improvement in the quality of the patient's health by managing other issues that may not have been evident prior to the diagnosis (Henderson et al., 2014) .
There (Henderson et al., 2014) . Several studies have shown that recurrence risk and the parents' perception of this risk plays a large role in their reproductive decision-making (Bailey, Skinner, & Sparkman, 2003; Selkirk, Veach, Lian, Schimmenti, & LeRoy, 2009) , as does the potential to use technology such as PGD or prenatal exclusion testing (Decruyenaere et al., 2007; Downing, 2005; Klitzman, Thorne, Williamson, Chung, & Marder, 2007) .
The most significant difference between positive and negative results is seen in GC options. The downstream effect of WES results can extend beyond treatment and medical decisions and also extend beyond the proband. Without a genetic diagnosis, families that have a child with a presumed genetic condition that has not been confirmed molecularly do not have the option to pursue targeted prenatal testing, preimplantation genetic testing, or testing for at-risk relatives. The availability of support groups specific to the genetic diagnosis is also something that may have effects on the entire family, such as allowing families to identify individuals with the same diagnosis, reducing feelings of isolation, and providing assistance in navigating health and social care as relevant to the diagnosis and other forms of support and connection (Plumridge et al., 2011) .
These GC options often come with receiving any genetic diagnosis, the benefits of which cannot be overstated. While receiving a genetic diagnosis is possible from testing methodologies other than WES, the high detection rate of WES compared to other genetic tests suggests a greater chance of receiving a genetic diagnosis and thus the availability of these GC options. One study investigating the clinical impact of CMA reported that even of the families whose children did not receive direct changes to management based on their positive results, 57% were still relieved to finally have a genetic explanation for their child's medical issues (Saam et al., 2008) . It is important to consider the psychosocial implications and how family members may be impacted from receiving a diagnosis on WES.
Considering psychosocial factors as well as the cost-benefit ratio of WES compared to the traditional diagnostic workup (Monroe et al., 2016; Stark et al., 2017; Vissers et al., 2017) 
| Study limitations and future directions
| CON CLUS ION
This is the first study to look specifically at differences in medical management and GC options before and after WES by type of result (positive vs. negative). Statistically significant differences preto post-WES were observed for participants with both positive and negative results in genetic testing, imaging, and metabolic testing.
All of these differences, with the exception of a small portion of differences in imaging for the positive group, were discontinuation of these tests following WES results. Additionally, in the positive group, statistically significant differences were identified in lifestyle recommendations, recurrence risk, reproductive options, testing availability for family members, and support groups. The positive group was significantly more likely to experience differences in these variables and to receive specialist referrals than the negative group. These findings provide evidence that both positive and negative WES results may influence medical management and GC options.
| COMPLIAN CE WITH E THIC AL S TANDARDS
